Stocklytics Platform
Asset logo for symbol PBYI
Puma Biotechnology
High Value
Penny Stock
Asset logo for symbol PBYI


Key Stats
Prev. Close$3.95
Next Earnings Date-
Dividend Yield %-
Market Cap$165.94M
Day Range3.58
52 Week Range2.13
Earnings Growth %-
Payout Ratio-
Industry average yield2.86%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_down0.16%
US Marketarrow_drop_up0.90%
PBYI / Market
PBYI lose to the US Market which returned 0.90% over the last twenty four hours.
PBYI / Healthcare Sector
PBYI lose to the US Healthcare sector which returned -0.16% over the last twenty four hours.

Puma Biotechnology (PBYI) Statistics

Puma Biotechnology Inc (PBYI) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. The company's lead product, Nerlynx (neratinib), is an oral kinase inhibitor indicated for the extended adjuvant treatment of HER2-positive early stage breast cancer. PBYI stock statistics demonstrate the company's performance in the market. Valuation metrics provide insights into the company's worth and potential investment opportunities. Fundamental analysis helps investors understand the financial health and stability of the company.

Puma Biotechnology Inc's PBYI stock performance compared to the sector is a significant measure for investors. It helps evaluate the company's relative performance and its position within the industry. Revenue per share is a critical metric that reflects the company's ability to generate profits and indicates its efficiency in utilizing its resources. Enterprise to EBITDA ratio is an important valuation metric that measures a company's operating performance and compares it to its total debt. Puma Biotechnology Inc's PBYI profit margin signifies the percentage of revenue the company retains after deducting expenses. Total debt reflects the company's financial leverage and its ability to meet its financial obligations. Finally, PBYI's gross profit is a key indicator of the company's profitability and efficiency in managing costs.

add Puma Biotechnology  to watchlist

Keep an eye on Puma Biotechnology

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

How has Puma Biotechnology (PBYI) stock's performance compared to its sector and the market over the past year?

Over the past year, Puma Biotechnology (PBYI) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 27.53%, Puma Biotechnology has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 49.54%, it has fallen short of the market average. This comparison highlights Puma Biotechnology 's performance relative to both its sector and the overall market over the last year.

What is the PE ratio of Puma Biotechnology (PBYI) stock?

The PE (Price to Earnings) ratio of Puma Biotechnology (PBYI) is currently 11.62. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.

What is the EPS of Puma Biotechnology (PBYI) stock?

The Earnings Per Share (EPS) for Puma Biotechnology (PBYI), calculated on a diluted basis, is $0.32. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

What is the operating margin of Puma Biotechnology (PBYI) stock?

The operating margin for Puma Biotechnology (PBYI) is -5.25%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of Puma Biotechnology (PBYI) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Puma Biotechnology (PBYI) is $42.07M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How much debt does Puma Biotechnology (PBYI) have?

Puma Biotechnology (PBYI) has a total debt of $110.74M. The net debt, which accounts for cash and cash equivalents against the total debt, is $33.98M.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level